e-learning
resources
Copenhagen 2005
Monday 19.09.2005
COPD - treatment II
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Evaluation of respiratory muscles‘ function in COPD patients treated with tiotropium
O. V. Myronenko (Dniepropetrovsk, Ukraine)
Source:
Annual Congress 2005 - COPD - treatment II
Session:
COPD - treatment II
Session type:
Thematic Poster Session
Number:
1941
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
O. V. Myronenko (Dniepropetrovsk, Ukraine). Evaluation of respiratory muscles‘ function in COPD patients treated with tiotropium. Eur Respir J 2005; 26: Suppl. 49, 1941
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Optimizing invasive ventilation for SMA type 1 children who are receiving the gene therapy
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
The physiology of breathlessness
Related content which might interest you:
Once-daily QVA149 demonstrates superior improvements in patient-reported dyspnea compared to tiotropium in patients with moderate-to-severe COPD: The BLAZE study
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
Pimax in the evaluation of respiratory muscles function in the COPD patients
Source: Annual Congress 2007 - Respiratory muscles and breathing techniques in obstructive and neuromuscular diseases
Year: 2007
QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK study
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013
Once-daily QVA149 provides superior improvements in lung function compared with glycopyrronium and tiotropium in severe COPD patients: A 52 week pooled analysis
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013
QVA149 improves dyspnoea and lung function versus tiotropium in symptomatic patients using LABA/ICS preceding study enrolment: The BLAZE study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Patients with severe COPD show significant improvements in dyspnea and lung function with once-daily QVA149: The BLAZE study
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
Effects of acute dual bronchodilator treatment (tiotropium + olodaterol) on cardiopulmonary interactions in hyperinflated patients with COPD
Source: International Congress 2018 – Advances in exercise physiopathology
Year: 2018
Respiratory muscles in COPD patients
Source: Annual Congress 2010 - Lung imaging
Year: 2010
Effect of tiotropium compared to salmetrol on dynamic hyperinflation in patients with chronic obstructive pulmonary disease
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016
The fixed-dose combination of tiotropium + olodaterol has a rapid onset of action in patients with COPD
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015
Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
The evaluation of respiratory muscle functions in patients with severe COPD
Source: Eur Respir J 2004; 24: Suppl. 48, 288s
Year: 2004
Replacing oxytropium with tiotropium significantly improves pulmonary function in patients with COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 213s
Year: 2006
Evaluation of the individual bronchodilator response in patients with severe COPD
Source: Eur Respir J 2002; 20: Suppl. 38, 246s
Year: 2002
Efficacy of respiratory muscles training in COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 719s
Year: 2005
QVA149 showed significant improvements in lung function and health status and was well tolerated versus glycopyrronium and tiotropium in patients with severe COPD: The SPARK study
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014
Improvements in inspiratory capacity with tiotropium in patients with COPD
Source: Eur Respir J 2002; 20: Suppl. 38, 491s
Year: 2002
QVA149 provides superior peak lung function in patients with COPD
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
Acute bronchodilator response does not predict health outcomes in patients with COPD treated with tiotropium
Source: Annual Congress 2009 - Next generation bronchodilators
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept